価格表

在庫・価格 : 2024年05月04日 04時31分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
BCMA, Human, DuoSet Kit <TNFRSF17, DuoSet Kit>
データシート※最新のデータシートでない場合があります
DY193 RSDアールアンドディー システムス
R&D Systems, Inc.
1 kit ¥141,000
(未発注)
追加

在庫・価格 : 2024年05月04日 04時31分 現在

BCMA, Human, DuoSet Kit <TNFRSF17, DuoSet Kit>

  • 商品コード:DY193
  • メーカー:RSD
  • 包装:1kit
  • 価格: ¥141,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Thompson SA et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 2010 Jan;30(1):99-105
Thompson SA et al
2010/01/01
Sample Type: Serum PubMed
2 Schuh E et al. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. J. Immunol. 2017 Apr;198(8):3081-3088
Schuh E et al
2017/01/01
Sample Type: Cell Lysates PubMed
3 Cohen AD et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 2019 03;129(6):2210-2221
Cohen AD et al
2019/01/01
PubMed
4 Perez-Amill L et al. Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica 2021 01;106(1):173-184
Perez-Amill L et al
2021/01/01
PubMed
5 Piantoni S et al. Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Res
Piantoni S et al
2021/01/01
Species: Human PubMed
6 Robinson T et al. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells 2020 11;9(12)
Robinson T et al
2020/01/01
Species: Human PubMed
7 Visram A et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J 2021 Jun;11(6):120
Visram A et al
2021/01/01
Species: Human PubMed
  • No.: 1
  • 文献情報:
    Thompson SA et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 2010 Jan;30(1):99-105
    Thompson SA et al
    2010/01/01
  • 備考:
    Sample Type: Serum
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Schuh E et al. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. J. Immunol. 2017 Apr;198(8):3081-3088
    Schuh E et al
    2017/01/01
  • 備考:
    Sample Type: Cell Lysates
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Cohen AD et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 2019 03;129(6):2210-2221
    Cohen AD et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Perez-Amill L et al. Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica 2021 01;106(1):173-184
    Perez-Amill L et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Piantoni S et al. Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Res
    Piantoni S et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Robinson T et al. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells 2020 11;9(12)
    Robinson T et al
    2020/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Visram A et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J 2021 Jun;11(6):120
    Visram A et al
    2021/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed